Designing new-to-nature terpenes for next-generation ingredients. Cyterra develops programmable terpene chemistry to unlock new ingredient opportunities in flavors, fragrances, repellents, and adjacent specialty markets. By combining deep-chemistry-guided enzyme engineering, biocatalysis, and bioprocess design, Cyterra creates access to both established terpene products and new-to-nature terpene ingredients with novel performance profiles. Built on a strong scientific track record and an industry-oriented development model, the company’s vertically integrated technology stack enables faster development cycles, greater predictability, and scalable routes to differentiated molecular value. Based in Mainz, Cyterra is building new biological value chains for industries where innovation, quality, and supply security are critical. We turn terpene complexity into your competitive advantage.
Colorectal Cancer Alliance
The Colorectal Cancer Alliance is the nation’s leading nonprofit dedicated to colorectal cancer. Together with a nation of passionate allies, we advocate for prevention, magnify support, and accelerate research to end this disease. | The Colorectal Cancer Alliance empowers a nation of passionate and determined allies to prevent, treat, and overcome colorectal cancer in their lives and communities. Founded in 1999 and headquartered in Washington, D.C., the Alliance advocates for prevention, magnifies support, and accelerates research. We are the largest national nonprofit dedicated to colorectal cancer, and we exist to end this disease in our lifetime. | .
COD Research USA Inc
COD Research is a leading CRO based in the US and India, specializing in global clinical trials and pharmacovigilance services. With a strong focus on biosimilar trials worldwide, we offer tailored solutions, ensuring quality, compliance, and client satisfaction. Our commitment is to contribute to the advancement of healthcare by delivering reliable and efficient services on an international scale. | We are a technical full-service Contract Research Organization (CRO) that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly integrate with your teams, whether you require functional services for global studies or tailored on-site and off-site support. | We are a technical Full Service CRO that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly adapt to client requirements, whether you require functional solutions or global studies or tailored on-site and off-site support.
Celestia Diagnostics
Celestia Diagnostics develops lab tests and clinical bioinformatics systems to aid in the diagnosis and treatment of chronic complex conditions such as Long COVID, ME/CFS, and POTS.
Barrington James
Barrington James are an industry leading, global recruitment business that exclusively serves the Pharmaceutical, Biotechnology and Medical Device sectors. With offices all over the world and hundreds of specialists dedicated to sourcing exceptional talent, we have the capacity and capabilities to deliver world-class recruitment solutions to Life Science companies of all sizes.
Apxora
APXORA is an agentic AI SaaS platform supporting pharma, biotech, and medtech organizations by connecting financial and commercial decisions with clinical development and R&D through deployable, enterprise‑ready AI workflows. APXORA offers four core solutions: Asset Lifecycle Manager, Portfolio Manager, Clinical Navigator and Research Nexus. They can be deployed independently or as a connected suite, helping teams break down silos, meet security requirements, and adapt seamlessly to existing infrastructure. Together, these solutions create a built-in workflow that not only mirrors but optimizes decision-making. The result is a continuously connected closed loop system spanning early research through portfolio strategy. The platform can be extended with new tools or integrated with legacy systems, forming a living digital twin of the enterprise that strengthens connectivity, accelerates decisions, and improves efficiency at scale. Asset Lifecycle Manager The platform is a dynamic platform built to manage the full lifecycle of strategic assets. From inception to retirement. It enables users to model, monitor, and optimize the performance of each asset across its entire lifecycle. With advanced simulation tools and powered by agentic AI, users can evaluate how market dynamics, pricing strategies, competitive changes, and operational variables impact asset viability over time. Portfolio Manager The platform represents the culmination of a fully integrated decision support ecosystem, connecting every stage of enterprise value creation from early research signals to long term portfolio performance. Built for complex, innovation driven organizations, the Enterprise Suite fosters seamless collaboration across R&D, asset lifecycle management, and strategic planning. Clinical Navigator Clinical Navigator helps clinical teams design, simulate, and optimize trials using patient-level digital twins and predictive models. Built on generative AI and custom LLMs, it enables faster, smarter trial design and identifies regulatory analogs from FDA and EMA landscapes to guide trial planning. Research Nexus Research Nexus enables teams to generate hypotheses, identify novel targets, and explore drug repurposing opportunities. It provides a custom-built knowledge graph as the foundation for agent orchestration and LLM capabilities, unifying scientific and clinical data for rapid exploration and decision-making.
Accelsiors Gmbh
Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2025 in the German Pavilion to explore how we can advance your next clinical breakthrough. At Accelsiors CRO, we accelerate biopharmaceutical innovation through a science-driven, patient-centric approach. As a global, full-service CRO, we provide tailored clinical trial solutions designed to de-risk development, optimize timelines, and bring transformative therapies to market faster. With a proven track record in global clinical development, we navigate the complexities of modern drug research—from early-stage clinical development to regulatory approvals and patient-centric trials. Our strategic approach, cutting-edge AI analytics, and deep therapeutic expertise ensure seamless execution and measurable outcomes. | Accelsiors CRO – Science-Driven Clinical Excellence Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2026 in the German Pavilion to explore how we can advance your next clinical breakthrough. Let’s discuss how we can accelerate your next clinical breakthrough with Accelerant™, our proprietary Penta-Helix approach—a unique integration of science, patient-centricity, Quality by Design, AI-driven state-of-the-art technologies, and speed with cost-effectiveness at every stage of clinical development.
A2 Healthcare
A2 Healthcare（A2）, a Japan-Taiwan industry leader for clinical development, spearheads global new drug development in Japan from its new US office in Boston area. A2 is the expert for clinical development in Japan and Taiwan. We are interested to invest in our partner’s pipeline for entering drug development, especially for drugs which are already marketed or under development outside of Japan. Clinical Development: A2 is the leading Japanese CRO providing contracted services in the clinical stage. A2 have the capability and experience to support our partners from early to late phases in any therapeutic area, as well as regulatory consultation and submission. A2 is a subsidiary of ITOCHU Corporation which is one of the largest Japanese company and were awarded the Best CRO of the Citeline Intelligence Award 2023. Pipeline Investment A2’s “Pipeline Accelerator Program (PAP)” supports the development of novel drug candidates enter Japanese market by becoming co-developers with the sponsor. In other words, we will invest in your clinical development cost. Through the program, we will enable domestic and foreign biotech startups as well as pharmaceutical companies for entering the Japanese market with a much lower hurdle. | A2 Healthcare Corporation (A2) is a Japan-based full-service CRO and a core member of the ITOCHU Group, one of the largest Japanese trading and investment conglomerates. With approximately 1,300 employees and offices in Tokyo (HQ), Osaka, Taiwan, and Boston, we focus on helping overseas biotech and pharma companies enter and succeed in the Japanese and Taiwanese markets. A2 has been recognized for excellence in clinical operations and partner satisfaction, receiving the Best CRO/CDMO award (2023) and Best Contract Research Organization award (2025) at the Citeline Pharma Intelligence / Citeline Japan Awards. Key points about A2, the ITOCHU Group and our Japan-entry platform: ◆A2 operates J-STEP (Japan Strategic Entry Platform), a one-stop service platform developed together with ITOCHU to support overseas companies across the full product lifecycle in Japan. ◆J-STEP services include: -Japan market and regulatory assessment, PMDA / ICCC strategy, and early pricing and access considerations. -Japan clinical development planning and execution aligned with global programs. -CMO/CDMO coordination and supply chain support tailored to modality. -NDA support, PMS, real-world evidence (RWE) studies, safety, logistics, and MAH services. -Business development and out-licensing support to Japanese pharma companies using ITOCHU’s local network. ◆In 2026, ITOCHU Corporation acquired 100% of CoreMed Co., Ltd., a leading Japanese regulatory and development-strategy consulting firm. ◆CoreMed provides consulting from early development strategy and CMC evaluation through PMDA consultations and marketing authorization applications, supported by a strong network with EU and US regulatory experts. ◆By combining CoreMed’s regulatory and scientific expertise with A2’s clinical operational capabilities, the ITOCHU Group offers integrated “Strategy + Execution” support for Japan, from first regulatory assessment to approval and post-marketing. ◆Therapeutic area experience spans oncology, rare diseases, regenerative medicine and ATMPs, infectious diseases and vaccines, as well as major and specialty indications. ◆Phase I through Phase III, PMS, and RWE studies, including: -Regulatory and clinical strategy development. -PMDA meeting preparation and briefing packages. -Site selection, site management, monitoring, data management, biostatistics, medical writing, safety, and project management. -ICCC coordination and regulatory submissions. -Post-marketing surveillance and observational research. ◆As part of the ITOCHU Group, A2 can also support: -Partnering and out-licensing between overseas biotech and Japanese pharma. -Flexible collaboration models such as co-development, risk sharing, and selective financial support for Japan-focused assets. -Strategic use of ITOCHU’s global networks, including ITC Venture Partners in Silicon Valley and A2’s Boston office. ◆We are looking to connect with: -Overseas biotech and pharma companies seeking a Japan development and regulatory partner. -Companies interested in one-stop Japan market entry using J-STEP. -Partners exploring co-development, risk sharing, or out-licensing opportunities for the Japanese market. Our goal is Your Goal.